Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples